Andrographis paniculata/Finding
One finding, on its own
A single claim from the graph, with the evidence strength computed from its study, the sentence it was drawn from, and the paper. This address does not change.
Andrographis paniculata — no detected effect on expanded Disability Status Scale (EDSS)
Evidence strength: moderate.FindingNull result“The EDSS score during the total period of treatment was similar for the A. paniculata and the placebo groups, and no significant differences were observed.”
Quoted verbatim from Andrographis paniculata decreases fatigue in patients with relapsing-remitting multiple sclerosis: a 12-month double-blind placebo-controlled pilot study.. - Study
- RCT
- Duration
- 12 months
- Dose
- one 170 mg tablet every 12 h
- Population
- Adults aged 18-50 with relapsing-remitting multiple sclerosis, all receiving interferon beta-1a
Andrographis paniculata decreases fatigue in patients with relapsing-remitting multiple sclerosis: a 12-month double-blind placebo-controlled pilot study.2016PMID:2721527410.1186/s12883-016-0595-2Permalink
To cite this finding: https://catalystproject.ai/e/01M5MFSTZW9W43M99ZHSXWC9YK